Alexandra Hughes-Wilson - 22 May 2024 Form 4/A Insider Report for Mereo BioPharma Group plc (MREO)

Role
Chief Patient Access and Commercial Planning
Signature
/s/ Christine Fox, by power of attorney
Issuer symbol
MREO
Transactions as of
22 May 2024
Net transactions value
$0
Form type
4/A
Filing time
11 Jun 2024, 16:18:09 UTC
Date Of Original Report
23 May 2024
Previous filing
26 Jan 2024
Next filing
25 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding MREO American Depositary Shares representing Ordinary Shares 7,650 22 May 2024 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.
F2 This Amended Form 4 amends the Form 4 filed by the Reporting Person on May 23, 2024 (the "Original Form 4"). The transactions reported in the Original Form 4 were canceled in their entirety prior to settlement and, as a result, no shares were transferred.

Remarks:

Chief Patient Access and Commercial Planning